Mankind Pharma IPO: Mankind Pharma IPO: Reasonably priced, investors may join the company on its ‘Bharat-to-India’ quest

Rajeev Juneja, Vice Chairman & Managing Director at Mankind Pharma Ltd. image courtesy: company.


Adopting a contrarian strategy, Mankind Pharma chose to tap into small-town markets — an approach that paid rich dividends. Having established a solid base there, and robust financials, it has been increasing its focus on tier-I cities and metros in the last few years. In its next leg of growth, can it sustain the momentum and move up the ranks?

It isn’t the most opportune time for initial public offerings (IPOs), given the subdued broader market conditions. But Mankind Pharma, the fourth-largest pharmaceutical company in the Indian market, is all set for a public listing. Its business is largely resilient, as the Indian pharma market continues to grow at 8%-10% and offer good returns to branded generic-drug companies. Mankind Pharma has outperformed the Indian pharma market growth in

  • SAVE

Uh-oh! This is an exclusive story available for selected readers only.

Worry not. You’re just a step away.

Why ?

  • Exclusive Economic Times Stories, Editorials & Expert opinion across 20+ sectors

  • Stock analysis. Market Research. Industry Trends on 4000+ Stocks

  • Clean experience with
    Minimal Ads

  • Comment & Engage with ET Prime community

  • Exclusive invites to Virtual Events with Industry Leaders

  • A trusted team of Journalists & Analysts who can best filter signal from noise

  • ​Get 1 Year Complimentary Subscription of TOI+ worth Rs.799/-​

Leave a Reply

Your email address will not be published. Required fields are marked *